(0.10%) 5 522.50 points
(0.14%) 39 898 points
(0.21%) 19 793 points
(-0.02%) $81.61
(0.53%) $2.83
(-0.25%) $2 338.50
(0.24%) $29.60
(0.42%) $1 006.00
(0.03%) $0.932
(-0.04%) $10.53
(0.01%) $0.788
(-0.85%) $87.25
-0.78% $ 32.01
Live Chart Being Loaded With Signals
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 287 834 |
Średni wolumen | 597 570 |
Kapitalizacja rynkowa | 1.88B |
EPS | $3.41 ( Q1 | 2024-05-07 ) |
Następna data zysków | ( $-0.680 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
12.60 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0410 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-13 | Patel Dinesh V Ph D | Sell | 1 000 | Common Stock |
2024-06-07 | Waddill William D. | Buy | 8 000 | Common Stock |
2024-06-07 | Waddill William D. | Sell | 8 000 | Stock Option (right to buy) |
2024-06-07 | Waddill William D. | Sell | 8 000 | Common Stock |
2024-06-07 | Patel Dinesh V Ph D | Sell | 35 000 | Common Stock |
INSIDER POWER |
---|
59.86 |
Last 97 transactions |
Buy: 2 539 640 | Sell: 469 541 |
Wolumen Korelacja
Protagonist Therapeutics Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ICFI | 0.86 |
SRTS | 0.854 |
KYMR | 0.846 |
PPH | 0.846 |
CREX | 0.833 |
REYN | 0.829 |
REGN | 0.828 |
EOLS | 0.822 |
MRUS | 0.817 |
LRMR | 0.813 |
10 Najbardziej negatywne korelacje | |
---|---|
VALN | -0.806 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Protagonist Therapeutics Korelacja - Waluta/Towar
Protagonist Therapeutics Finanse
Annual | 2023 |
Przychody: | $60.00M |
Zysk brutto: | $56.69M (94.48 %) |
EPS: | $-1.390 |
FY | 2023 |
Przychody: | $60.00M |
Zysk brutto: | $56.69M (94.48 %) |
EPS: | $-1.390 |
FY | 2022 |
Przychody: | $26.58M |
Zysk brutto: | $25.55M (96.12 %) |
EPS: | $-2.52 |
FY | 2021 |
Przychody: | $27.36M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.71 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej